Pharmacogenetic variation is common and an established driver of response for many
drugs. There has been tremendous progress in pharmacogenetics knowledge over the last …

Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and
enhancing therapeutic efficacy for commonly used drugs that treat a wide range of …

Background In recent years, β-blockers such as metoprolol have been upgraded to first-line
antihypertensive drugs. However, metoprolol demonstrates poor prognosis effects on …

Introduction: To study the effects of drug-induced CYP2D6 activity inhibition and genetic
polymorphisms on fluoxetine metabolism, rat liver microsomes (RLMs) and SD rats were …

Pharmacogenomic (PGx) testing to inform antidepressant medication selection and dosing
is gaining attention from healthcare professionals, patients, and payors in Australia …

The toxicity of Orellanine (OR), a significant factor in mushroom poisoning, has severe
effects on the kidneys, particularly the proximal tubules. This study investigated the acute …

Frequencies of pharmacogenetic (PGx) variants are known to differ substantially across
populations but much of the available PGx literature focuses on one or a few population …

Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal
drug selection and dosing based on an individual's genotype in conjunction with other …

Abstract Cytochrome P450 2D6 (CYP2D6) is important for metabolism of 20%–25% of all
clinically used drugs. Many known genetic variants contribute to the large interindividual …

Background Clinical pharmacogenetic implementation guidelines for statin therapy are
derived from evidence of primarily Eurocentric study populations. Functional SLCO1B1 …